Full-Length SMN Transcript in Extracellular Vesicles as Biomarker in Individuals with Spinal Muscular Atrophy Type 2 Treated with Nusinersen

被引:6
作者
Trifunov, Selena [1 ,6 ]
Natera-de Benito, Daniel [1 ,2 ]
Carrera-Garcia, Laura [1 ,2 ]
Codina, Anna [1 ]
Exposito-Escudero, Jesica [1 ,2 ]
Ortez, Carlos [1 ]
Medina, Julita [4 ]
Torres Alcala, Soraya [3 ]
Bernal, Sara [5 ,6 ]
Alias, Laura [5 ,6 ]
Badosa, Carmen [1 ]
Balsells, Sol [7 ]
Alcolea, Daniel [3 ]
Nascimento, Andres [1 ,2 ,6 ]
Jimenez-Mallebrera, Cecilia [1 ,6 ,8 ]
机构
[1] Inst Recerca St Joan De Deu, Appl Res Neuromuscular Dis, Barcelona, Spain
[2] Hosp San Juan Dios, Dept Neurol, Neuromuscular Unit, Barcelona, Spain
[3] Univ Autonoma Barcelona, Inst Invest Biomed St Pau Hosp St Pau, Hosp Santa Creu & St Pau, Dept Neurol, Barcelona, Spain
[4] Hosp St Joan De Deu, Rehabil & Phys Unit Dept, Barcelona, Spain
[5] Univ Autonoma Barcelona, Inst Invest Biomed St Pau Hosp St Pau, Dept Genet, Barcelona, Spain
[6] Inst Salud Carlos III, Biomed Network Res Ctr Rare Dis CIBERER, Madrid, Spain
[7] Inst Recerca St Joan De Deu, Stat Dept, Barcelona, Spain
[8] Univ Barcelona, Dept Genet Microbiol & Stat, Barcelona, Spain
关键词
Biomarkers; cerebrospinal fluid; nusinersen; response predictors; serum; spinal muscular atrophy; SHAM CONTROL; EXPRESSION; EXOSOMES;
D O I
10.3233/JND-230012
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Three therapeutic strategies have radically changed the therapeutic scenario for spinal muscular atrophy (SMA). However, therapeutic response differs between individuals. There is a need to identify biomarkers to further assess therapeutic response and to better understand which variables determine the extent of response. Methods: We conducted a study using an optimized digital droplet PCR-based method for the ultra-sensitive detection of SMN transcript in serum EVs from SMA 2 individuals treated with nusinersen over 14 months. In parallel, we investigated levels of serum and CSF neurofilament heavy chain (pNF-H) in the same cohort. Results: Expression of flSMN transcript in EVs of SMA 2 individuals prior to nusinersen was lower than in controls (0.40 vs 2.79 copies/ul; p < 0.05) and increased after 14 months of nusinersen (0.40 vs 1.11 copies/ul; p < 0.05). The increase in flSMN with nusinersen was significantly higher in younger individuals (p < 0.05). Serum pNF-h was higher in non-treated individuals with SMA 2 than in controls (230.72 vs 22.88 pg/ml; p < 0.05) and decreased with nusinersen (45.72 pg/ml at 6 months, 39.02 pg/ml at 14 months). CSF pNF-h in SMA 2 individuals also decreased with nusinersen (248.04 pg/ml prior to treatment, 197.10 pg/dl at 2 months, 104.43 pg/dl at 6 months, 131.03 pg/dl at 14 months). Conclusions: We identified an increase of flSMN transcript in serum EVs of SMA 2 individuals treated with nusinersen that was more pronounced in the younger individuals. Our results indicate that flSMN transcript expression in serum EVs is a possible biomarker in SMA to predict or monitor the response to treatment.
引用
收藏
页码:653 / 665
页数:13
相关论文
共 54 条
[1]   Treatment of spinal muscular atrophy cells with drugs that upregulate SMN expression reveals inter- and intra-patient variability [J].
Also-Rallo, Eva ;
Alias, Laura ;
Martinez-Hernandez, Rebeca ;
Caselles, Lidia ;
Barcelo, Maria J. ;
Baiget, Montserrat ;
Bernal, Sara ;
Tizzano, Eduardo F. .
EUROPEAN JOURNAL OF HUMAN GENETICS, 2011, 19 (10) :1059-1065
[2]   Prognostic Factors and Treatment-Effect Modifiers in Spinal Muscular Atrophy [J].
Baranello, Giovanni ;
Gorni, Ksenija ;
Daigl, Monica ;
Kotzeva, Anna ;
Evans, Rachel ;
Hawkins, Neil ;
Scott, David A. ;
Mahajan, Anadi ;
Muntoni, Francesco ;
Servais, Laurent .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (06) :1435-1454
[3]   Risdiplam in Type 1 Spinal Muscular Atrophy [J].
Baranello, Giovanni ;
Darras, Basil T. ;
Day, John W. ;
Deconinck, Nicolas ;
Klein, Andrea ;
Masson, Riccardo ;
Mercuri, Eugenio ;
Rose, Kristy ;
El-Khairi, Muna ;
Gerber, Marianne ;
Gorni, Ksenija ;
Khwaja, Omar ;
Kletzl, Heidemarie ;
Scalco, Renata S. ;
Seabrook, Timothy ;
Fontoura, Paulo ;
Servais, Laurent .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (10) :915-923
[4]   Decay in survival motor neuron and plastin 3 levels during differentiation of iPSC-derived human motor neurons [J].
Boza-Moran, Maria G. ;
Martinez-Hernandez, Rebeca ;
Bernal, Sara ;
Wanisch, Klaus ;
Also-Rallo, Eva ;
Le Heron, Anita ;
Alias, Laura ;
Denis, Cecile ;
Girard, Mathilde ;
Yee, Jiing-Kuan ;
Tizzano, Eduardo F. ;
Yanez-Munoz, Rafael J. .
SCIENTIFIC REPORTS, 2015, 5
[5]   Pediatric SMA patients with complex spinal anatomy: Implementation and evaluation of a decision-tree algorithm for administration of nusinersen [J].
Carrera-Garcia, Laura ;
Muchart, Jordi ;
Lazaro, Juan Jose ;
Exposito-Escudero, Jessica ;
Cuadras, Daniel ;
Medina, Julita ;
de Basea, Magda Bosch ;
Colomer, Jaume ;
Jimenez-Mallebrera, Cecilia ;
Ortez, Carlos ;
Natera-de Benito, Daniel ;
Nascimento, Andres .
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2021, 31 :92-101
[6]   The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy [J].
d'Ydewalle, Constantin ;
Ramos, Daniel M. ;
Pyles, Noah J. ;
Ng, Shi-Yan ;
Gorz, Mariusz ;
Pilato, Celeste M. ;
Ling, Karen ;
Kong, Lingling ;
Ward, Amanda J. ;
Rubin, Lee L. ;
Rigo, Frank ;
Bennett, C. Frank ;
Sumner, Charlotte J. .
NEURON, 2017, 93 (01) :66-79
[7]   Neurofilament as a potential biomarker for spinal muscular atrophy [J].
Darras, Basil T. ;
Crawford, Thomas O. ;
Finkel, Richard S. ;
Mercuri, Eugenio ;
De Vivo, Darryl C. ;
Oskoui, Maryam ;
Tizzano, Eduardo F. ;
Ryan, Monique M. ;
Muntoni, Francesco ;
Zhao, Guolin ;
Staropoli, John ;
McCampbell, Alexander ;
Petrillo, Marco ;
Stebbins, Christopher ;
Fradette, Stephanie ;
Farwell, Wildon ;
Sumner, Charlotte J. .
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2019, 6 (05) :932-944
[8]   Biochemical and clinical biomarkers in adult SMA 3-4 patients treated with nusinersen for 22 months [J].
De Wel, Bram ;
De Schaepdryver, Maxim ;
Poesen, Koen ;
Claeys, Kristl G. .
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2022, 9 (08) :1241-1251
[9]   Neuronal-Derived EV Biomarkers Track Cognitive Decline in Alzheimer's Disease [J].
Eren, Erden ;
Leoutsakos, Jeannie-Marie ;
Troncoso, Juan ;
Lyketsos, Constantine G. ;
Oh, Esther S. ;
Kapogiannis, Dimitrios .
CELLS, 2022, 11 (03)
[10]   Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy [J].
Finkel, R. S. ;
Mercuri, E. ;
Darras, B. T. ;
Connolly, A. M. ;
Kuntz, N. L. ;
Kirschner, J. ;
Chiriboga, C. A. ;
Saito, K. ;
Servais, L. ;
Tizzano, E. ;
Topaloglu, H. ;
Tulinius, M. ;
Montes, J. ;
Glanzman, A. M. ;
Bishop, K. ;
Zhong, Z. J. ;
Gheuens, S. ;
Bennett, C. F. ;
Schneider, E. ;
Farwell, W. ;
De Vivo, D. C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (18) :1723-1732